Biobehavioral Health

Toms River, New Jersey 08755-6434

8 studies enrolling now · 64 studies all time

What they study most

Acute Migraine With or Without Aura, Agitation, Agitation Associated With Alzheimer's Dementia, Agitation and Aggression in Alzheimer's Disease, Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer's Disease, Alzheimer´s Disease, Dementia, Dementia-related Psychosis, Depression, Depression - Major Depressive Disorder

Studies at this site

• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Recruiting now
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — Recruiting now
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease — Recruiting now
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Recruiting now
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia — Recruiting now
• Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type — Recruiting now
• An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1) — Recruiting now
• A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Recruiting now
• An Open-Label Study of Azetukalner in Major Depressive Disorder — Enrolling by invitation
• A Study to Test Different Doses of BI 1569912 in People With Depression — Completed
• Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder — Completed
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD — Running, not enrolling
• Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
• Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression — Completed
• Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD — Running, not enrolling
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Stopped early
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Completed
• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis — Completed
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Completed
• A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder — Completed
• Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations — Completed
• A Study of LY3451838 in Participants With Migraine — Completed
• Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents — Stopped early
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study — Completed
• Fasudil fOr redUcing elopemeNt and Spatial Disorientation — Completed
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine — Stopped early
• A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder — Completed
• Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine — Completed
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study — Completed
• A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants — Completed